calcimedica.com (CALI) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The visualized EV/EBITDA market trend for CalciMedica, Inc. (CALI) stands at 0.00. This biotech firm develops methods to combat acute inflammation, leveraging patents to expand within the global market. The business relies on the creation of calcium channel inhibitors applicable to lung injuries and pancreatitis. Meanwhile, CalciMedica, Inc. (CALI) adheres to bioethical principles and environmental standards across its laboratories.
calcimedica.com - analytical breakdowns and key metrics (CALI)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
- business earnings and investment ratios data:
CALI - Company Net Income|Projected Future Earnings CalciMedica, Inc.|CALI - Price to Earnings Ratio|Forward P/E Multiple CalciMedica|CALI - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CALI|CALI - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) CalciMedica|CALI - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth calcimedica.com|CALI - Earnings per share growth this year|Earnings growth forecast for next year CalciMedica, Inc.
- sales and revenue data:
Initial company analysis:CalciMedica Corp CALI
The EV/EBITDA multiple determines the total business value relative to its operating profit before depreciation, taxes, and interest. By analyzing this enterprise value to EBITDA chart, an investor sees the asset's real price accounting for debt load and stripped of accounting distortions. For CalciMedica, Inc. (CALI), this metric is critical as it reflects the market's revaluation of CRAC channel inhibition potential in anticipation of clinical trial results.
Competitors of CalciMedica, Inc. (CALI)
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|Vera Pharma - EV/EBITDA Multiple|Dianthus Corp (DNTH) - Enterprise Value to EBITDA Ratio|PHVS: EV/EBITDA Multiple|AbCellera (ABCL) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tourmaline Bio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PGEN|EV/EBITDA Multiple PHAR|Enterprise Value to EBITDA Ratio Nektar Corp NKTR|EV/EBITDA Multiple UPB (Upstream Bio Inc)|Total Company Value to Operating Income Before Depreciation Ratio zenasbio.com (ZBIO)|IMNM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Gossamer Bio Inc (GOSS) - Enterprise Value to EBITDA Ratio|KALV: EV/EBITDA Multiple|Company Value to EBITDA Septerna Pharma (SEPN)|PVLA (Pieris Pharmaceuticals) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation SVRA (savarapharma.com)|EV/EBITDA Multiple RIGL|Total Company Value to Operating Income Before Depreciation Ratio AnaptysBio Inc|EV/EBITDA Multiple ATXS (Astria Pharma)|ENGN - Enterprise Value to EBITDA Ratio|RAPT Therapeutics - EV/EBITDA Multiple|JBIO - EV/EBITDA Multiple|ACRS (Aclaris Therapeutics, Inc.) - Enterprise Value to EBITDA Ratio|Kyverna Therapeutics Inc. - Business Value to Operating Income Before Depreciation|TLSA (Tiziana Life Sciences PLC) - EV/EBITDA Multiple|Cabaletta Bio Inc (CABA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ventyx Biosciences (VTYX)|theratech.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AVTX (Avalo Therapeutics)|ELDN - Enterprise Value to EBITDA Ratio|AGEN: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Climb Bio, Inc CLYM|ZURA: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio atyrpharma.com|ADAG (Adagene Inc) - EV/EBITDA Multiple|EV/EBITDA Multiple Ikena Oncology, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Shattuck Labs, Inc. (STTK)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization EQ (equilliumbio.com)|EV/EBITDA Multiple CNTB (Connect Biopharma Holdings Limited)|Total Company Value to Operating Income Before Depreciation Ratio Immunic Therapeutics (IMUX)|ATRA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio IFRX|XFOR: EV/EBITDA Multiple|Adicet Bio, Inc. - Business Value to Operating Income Before Depreciation|CELU (Celularity Inc) - EV/EBITDA Multiple|EV/EBITDA Multiple inmunebio.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Barinthus Biotherapeutics plc (BRNS)|KZR (Kezar Life Sciences Inc.) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SAB Biotherapeutics, Inc SABS|AKTX - Enterprise Value to EBITDA Ratio|Enlivex Therapeutics, Ltd. - EV/EBITDA Multiple|QTTB - EV/EBITDA Multiple|GOVX (GeoVax) - Enterprise Value to EBITDA Ratio|Edesa Biotech Inc - Business Value to Operating Income Before Depreciation|IBIO (iBio Corp) - EV/EBITDA Multiple|Carisma Tx (CARM) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization XTL Biopharmaceuticals (XTLB)|Enterprise Value to EBITDA Ratio boltbio.com BOLT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization HCW Biologics HCWB|APVO - Enterprise Value to EBITDA Ratio|AIM: Enterprise Value to EBITDA Ratio|ADTX - EV/EBITDA Multiple|GRI Bio, Inc. (GRI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation XRTX|HIND (Vyome Holdings) - EV/EBITDA Multiple|Company Value to EBITDA Revelation Biosciences Inc REVB|EV/EBITDA Multiple INDP|Enterprise Value to EBITDA Ratio BiondVax Pharmaceuticals SCNI|EV/EBITDA Multiple AFMD (Affimed N.V.)|EV/EBITDA Multiple Allakos Inc ALLK|HOOK - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IGMS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ITOS: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Ocean Biomedical Corp|TCBP (TC Biopharm) - EV/EBITDA Multiple|thirdharmonicbio.com (THRD) - Total Company Value to Operating Income Before Depreciation Ratio
